# SLFN5

## Overview
SLFN5 is a gene that encodes the protein schlafen family member 5, which is part of the Schlafen protein family. This protein is characterized by its involvement in cell cycle regulation and cellular proliferation, primarily through its interactions with various cell cycle-related proteins. SLFN5 contains several functional domains, including a DNA binding domain, a P-loop NTPase domain, and a C-terminal helicase domain, which suggest its role in DNA replication and transcription regulation. It is predominantly localized in the nucleus and is subject to regulation by phosphorylation, which influences its interactions with protein phosphatase 2A (PP2A) and other cell cycle proteins. Beyond its role in normal cellular processes, SLFN5 is also implicated in cancer progression, where it modulates gene expression and signaling pathways associated with tumorigenesis and metastasis (Tu2023Progress; Wan2019SLFN5; Vit2022Human).

## Structure
SLFN5 is a protein characterized by a complex molecular structure comprising several distinct domains. It includes a N-terminal DNA binding domain (DBD), a P-loop NTPase domain, and a C-terminal helicase domain, which are integral to its function in cell cycle regulation (Vit2022Human). The protein also contains a canonical nuclear localization signal (NLS) and a nuclear export signal (NES), facilitating its transport into and out of the nucleus (Vit2022Human). 

SLFN5 is part of the third group of the Schlafen protein family and shares structural domains with other family members like SLFN11, SLFN13, and SLFN14. However, it lacks endoribonuclease activity, which is a unique feature within the family (Tu2023Progress). The protein contains the conserved domain COG2865, partially homologous to transcriptional regulatory factors and helicases, and a specific SWADL domain, characterized by the sequence Ser-Trp-Ala-Asp-Leu (Tu2023Progress). 

The C-terminal domain of SLFN5 is a putative helicase/ATPase domain, showing homology to superfamily I RNA/DNA helicases, and includes a zinc finger motif that may assist in nucleotide recognition or protein folding (Jo2022Structural). Phosphorylation is a common post-translational modification of SLFN5, influencing its interaction with protein phosphatase 2A (PP2A) and affecting cellular proliferation (Vit2022Human).

## Function
SLFN5, a member of the Schlafen gene family, plays a crucial role in cell cycle regulation and cell proliferation in healthy human cells. It is highly expressed in proliferating tissues and peaks during the S phase of the cell cycle. SLFN5 is involved in the transition from the S to G2 phase, interacting with protein phosphatase 2A (PP2A), particularly the PP2A-B55α complex, in a phosphorylation-dependent manner. This interaction is essential for normal cell cycle progression, as SLFN5's phosphorylation status affects its binding to PP2A-B55α, influencing cellular proliferation (Vit2022Human).

SLFN5 is localized in the nucleus, where it contains a DNA binding domain, a P-loop NTPase domain, and a C-terminal helicase domain. These domains suggest its involvement in DNA replication and transcription regulation (Jo2022Structural; Vit2022Human). The protein's phosphorylation and dephosphorylation are critical for its function, with CDK1-Cyclin B1 phosphorylating SLFN5 and PP2A-B55α dephosphorylating it, thus regulating the G2/M transition (Vit2022Human). SLFN5's role in these processes underscores its importance in maintaining normal cellular proliferation and viability (Vit2022Human).

## Clinical Significance
Alterations in the expression of the SLFN5 gene have been implicated in various cancers, including ovarian cancer, breast cancer, and gastric cancer. In ovarian cancer, SLFN5 is significantly upregulated in cancerous tissues compared to non-cancerous tissues. High SLFN5 expression is associated with advanced stages, metastasis, and poor prognosis, particularly in high-grade serous carcinoma. It promotes tumorigenesis and progression by facilitating epithelial-mesenchymal transition (EMT), a process critical for cancer metastasis (Xu2023SLFN5).

In breast cancer, SLFN5 expression is negatively correlated with metastasis. Lower SLFN5 levels are observed in metastatic breast cancer tissues. SLFN5 acts as a suppressor of metastasis by inhibiting the transcription of ZEB1, a key driver of EMT. Overexpression of SLFN5 induces a mesenchymal-to-epithelial transition (MET), reducing cancer cell invasion and metastasis (Wan2020Human).

In gastric cancer, SLFN5 expression in the stromal cells of the gastric mucosa is a potential prognostic indicator for the progression of intestinal metaplasia to gastric cancer. Its expression is associated with immune cell infiltration and may be regulated by interferon alpha (Companioni2016SCHLAFEN).

## Interactions
SLFN5 interacts with several proteins involved in cell cycle regulation and cancer progression. It binds to the serine/threonine-protein phosphatase 2A regulatory subunit B55α (PP2A-B55α), a crucial interaction for its function in cell cycle progression. This binding is regulated by phosphorylation at threonine residues, and a non-phosphorylatable version of SLFN5 impairs this interaction, highlighting the importance of phosphorylation in SLFN5's activity (Vit2022Human). SLFN5 also interacts with other proteins such as serine/threonine-protein phosphatase 5 (PP5), origin recognition complex subunit 2 (ORC2), and the APC/C activator protein CDC20, which are involved in the G2/M transition of the cell cycle (Vit2022Human).

In the context of cancer, SLFN5 modulates the expression of matrix metalloproteinase genes, including MT1-MMP, through the AKT/GSK-3β/β-catenin signaling pathway, affecting cancer cell migration and invasion (Wan2019SLFN5). It also interacts with STAT1 in glioblastoma multiforme to inhibit gene transcription driven by type I interferon (IFN) (Tu2023Progress). These interactions suggest that SLFN5 plays a multifaceted role in both cell cycle regulation and cancer progression.


## References


[1. (Tu2023Progress) Teng Tu, Ye Yuan, Xiaoxue Liu, Xin Liang, Xiaofan Yang, and Yue Yang. Progress in investigating the relationship between schlafen5 genes and malignant tumors. Frontiers in Oncology, September 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1248825, doi:10.3389/fonc.2023.1248825. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1248825)

[2. (Xu2023SLFN5) Qiao Ping Xu, Kui Deng, Zhen Zhang, and Hongkai Shang. Slfn5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer. Journal of Ovarian Research, February 2023. URL: http://dx.doi.org/10.1186/s13048-023-01103-7, doi:10.1186/s13048-023-01103-7. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13048-023-01103-7)

[3. (Jo2022Structural) Ukhyun Jo and Yves Pommier. Structural, molecular, and functional insights into schlafen proteins. Experimental &amp; Molecular Medicine, 54(6):730–738, June 2022. URL: http://dx.doi.org/10.1038/s12276-022-00794-0, doi:10.1038/s12276-022-00794-0. This article has 30 citations.](https://doi.org/10.1038/s12276-022-00794-0)

[4. (Wan2019SLFN5) Guoqing Wan, Yihao Liu, Jiang Zhu, Lijuan Guo, Chenhong Li, Yue Yang, Xuefeng Gu, Li-Li Deng, and Changlian Lu. Slfn5 suppresses cancer cell migration and invasion by inhibiting mt1-mmp expression via akt/gsk-3β/β-catenin pathway. Cellular Signalling, 59:1–12, July 2019. URL: http://dx.doi.org/10.1016/j.cellsig.2019.03.004, doi:10.1016/j.cellsig.2019.03.004. This article has 50 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2019.03.004)

[5. (Companioni2016SCHLAFEN) Osmel Companioni Nápoles, Amy C. Tsao, José Miguel Sanz-Anquela, Núria Sala, Catalina Bonet, María Luisa Pardo, Lin Ding, Ornella Simo, Milena Saqui-Salces, Verónica Parra Blanco, Carlos A. Gonzalez, and Juanita L. Merchant. Schlafen 5 expression correlates with intestinal metaplasia that progresses to gastric cancer. Journal of Gastroenterology, 52(1):39–49, March 2016. URL: http://dx.doi.org/10.1007/s00535-016-1202-4, doi:10.1007/s00535-016-1202-4. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00535-016-1202-4)

[6. (Vit2022Human) Gianmatteo Vit, Alexander Hirth, Nicolas Neugebauer, Bianca N. Kraft, Gianluca Sigismondo, Anna Cazzola, Claudia Tessmer, Joana Duro, Jeroen Krijgsveld, Ilse Hofmann, Michael Berger, Harald Klüter, Christof Niehrs, Jakob Nilsson, and Alwin Krämer. Human slfn5 and its xenopus laevis ortholog regulate entry into mitosis and oocyte meiotic resumption. Cell Death Discovery, December 2022. URL: http://dx.doi.org/10.1038/s41420-022-01274-0, doi:10.1038/s41420-022-01274-0. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-022-01274-0)

[7. (Wan2020Human) Guoqing Wan, Jiang Zhu, Xuefeng Gu, Yue Yang, Yihao Liu, Zhizheng Wang, Yuxia Zhao, Hailong Wu, Gang Huang, and Changlian Lu. Human schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of zeb1 transcription. British Journal of Cancer, 123(4):633–643, June 2020. URL: http://dx.doi.org/10.1038/s41416-020-0873-z, doi:10.1038/s41416-020-0873-z. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-020-0873-z)